SCLEROCAR

A Phase 2a clinical trial evaluating the safety and efficacy of T cells expressing a chimeric antigen receptor targeting CD19 (CAR-T cells) in patients with systemic sclerosis (SSc) resistant to immunosuppressive drugs

Condition studied : Systemic sclerosis
Treatment : Anti-CD19 CAR-T cells
Sponsor : Montpellier University Hospital
Principal Investigator : Pr. Christian Jorgensen
: CTIS 2024-519511-33-00
Investigator
Pr. Christian Jorgensen
Director
Rechercher sur le site